Találati lista | Tudóstér

001-es BibID:	BIBFORM049718
Első szerző:	Gyires Klára
Cím:	Gastric mucosal protection and central nervous system / Klara Gyires, József Németh, Zoltán S. Zádori
Dátum:	2013
ISSN:	1381-6128
Megjegyzések:	Several human and experimental data suggest the particular importance of gastric protective processes in maintaining mucosalintegrity. Both peripheral and central mechanisms are involved in this process. In the periphery, pre-epithelial mucus-bicarbonate layer,mucus, phospholipids, trefoil peptides, prostaglandins, heat shock proteins, sensory neuropeptides, nitric oxide, and hydrogen sulfide maymediate mucosal protection. In the central nervous system hypothalamus and dorsal vagal complex (DVC) have particular important rolein the regulation of centrally-induced gastroprotection. Stimulation of paraventricular nuclei either aggravates or inhibits the mucosal injurydepending on the ulcer model. Vagal nerve also has a dual role, its activation can induce mucosal injury (by high dose of thyrotropin-releasing hormone (TRH), electrical stimulation), however, integrity of vagal nerve is necessary for gastroprotection induced eitherperipherally (by PGE2, prostacyclin, adaptive cytoprotection), or centrally (e.g. by neuropeptides). The centrally induced gastroprotectionis likely to be vagal dependent, though vagal independent pathways have also been shown. Endomorphin-1 and endomorphin-2, selective?-opioid receptor ligands, proved to be highly potent and effective gastroprotective agents in ethanol ulcer model (0.03-3 pmol intracerebroventricularly).Inhibition of the degradation of endomorphins by diprotin A resulted in gastroprotective effect, indicating the potentialrole of these endogenous opioids in the regulation of gastric mucosal integrity. Endomorphin-2 injected intracerebroventricularly restoredthe reduced levels of CGRP and somatostatin in gastric mucosa induced by ethanol. In conclusion, neuropeptides expressed in dorsal vagalcomplex and hypothalamus may have a regulatory role in maintaining gastric mucosal integrity by stimulating the formation of mucosalprotective compounds.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Gastric Mucosal Protection Peripheral Central Mechanism Neuropeptides Endomorphins
Megjelenés:	Current Pharmaceutical Design. - 19 (2013), p. 34-39. -
További szerzők:	Németh József (1954-) (vegyész, analitikus) Zádori Zoltán S. (Farmakológia, gasztrointesztinális farmakológia)
Pályázati támogatás:	75965 OTKA TÁMOP-4.2.1/B-09/1/KMR-2010 TÁMOP
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM056832
Első szerző:	Szentmiklósi József András (farmakológus, klinikai laboratóriumi szakorvos)
Cím:	Chemistry, physiology, and pharmacology of [béta]-adrenergic Mechanisms in the heart : why are [béta]-blocker antiarrhythmics superior? / József A. Szentmiklósi, Norbert Szentandrássy, Bence Hegyi, Balázs Horváth, János Magyar, Tamás Bányász, Péter P. Nánási
Dátum:	2015
ISSN:	1381-6128
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban [béta]-adrenergic receptors [béta]-receptor blockers proarrhythmic mechanisms antiarrhythmic drugs cardiac ion currents cardiac remodeling
Megjelenés:	Current Pharmaceutical Design. - 21 : 8 (2015), p. 1030-1041. -
További szerzők:	Szentandrássy Norbert (1976-) (élettanász) Hegyi Bence (1987-) (élettanász) Horváth Balázs (1981-) (élettanász) Magyar János (1961-) (élettanász) Bányász Tamás (1960-) (élettanász) Nánási Péter Pál (1956-) (élettanász)
Pályázati támogatás:	OTKA-K100151 OTKA OTKA-PD101171 OTKA OTKA-K101196 OTKA OTKA-K109736 OTKA OTKA-NK104331 OTKA TÁMOP-4.2.2.A-11/1/KONV-2012-0045 TÁMOP
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM056739
Első szerző:	Szentmiklósi József András (farmakológus, klinikai laboratóriumi szakorvos)
Cím:	The janus face of adenosine : antiarrhythmic and proarrhythmic actions / A. József Szentmiklósi, Zoltán Galajda, Ágnes Cseppentő, Rudolf Gesztelyi, Zsolt Susán, Bence Hegyi, Péter P. Nánási
Dátum:	2015
ISSN:	1381-6128
Megjegyzések:	Adenosine is a ubiquitous, endogenous purine involved in a variety of physiological and pathophysiological regulatory mechanisms. Adenosine has been proposed as an endogenous antiarrhythmic substance to prevent hypoxia/ischemia-induced arrhythmias. Adenosine (and its precursor, ATP) has been used in the therapy of various cardiac arrhythmias over the past six decades. Its primary indication is treatment of paroxysmal supraventricular tachycardia, but it can be effective in other forms of supraventricular and ventricular arrhythmias, like sinus node reentry based tachycardia, triggered atrial tachycardia, atrioventricular nodal reentry tachycardia, or ventricular tachycardia based on a cAMP-mediated triggered activity. The main advantage is the rapid onset and the short half life (1- 10 sec). Adenosine exerts its antiarrhythmic actions by activation of A1 adenosine receptors located in the sinoatrial and atrioventricular nodes, as well as in activated ventricular myocardium. However, adenosine can also elicit A2A, A2B and A3 adenosine receptor-mediated global side reactions (flushing, dyspnea, chest discomfort), but it may display also proarrhythmic actions mediated by primarily A1 adenosine receptors (e.g. bradyarrhythmia or atrial fibrillation). To avoid the non-specific global adverse reactions, A1 adenosine receptor- selective full agonists (tecadenoson, selodenoson, trabodenoson) have been developed, which agents are currently under clinical trial. During long-term administration with orthosteric agonists, adenosine receptors can be internalized and desensitized. To avoid desensitization, proarrhythmic actions, or global adverse reactions, partial A1 adenosine receptor agonists, like CVT-2759, were developed. In addition, the pharmacologically "silent" site- and event specific adenosinergic drugs, such as adenosine regulating agents and allosteric modulators, might provide attractive opportunity to increase the effectiveness of beneficial actions of adenosine and avoid the adverse reactions.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Adenosinergic drugs antiarrhythmic action proarrhythmic effect adenosine A1 receptor activators partial A1 adenosine receptor agonists adenosine regulators allosteric receptor modulators drug development
Megjelenés:	Current Pharmaceutical Design. - 21 : 8 (2015), p. 965-976. -
További szerzők:	Galajda Zoltán (1962-) (szívsebész, érsebész) Cseppentő Ágnes (1953-) (orvos) Gesztelyi Rudolf (1969-) (kísérletes farmakológus) Susán Zsolt (1983-) (sebész) Hegyi Bence (1987-) (élettanász) Nánási Péter Pál (1956-) (élettanász)
Pályázati támogatás:	TÁMOP-4.2.2.A-11/1/KONV-2012-0045 TÁMOP Sebészet Kutatócsoport
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: